Jocelyn A Lewis DO (She/Her)
Pediatric Hematologic Oncology, Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology
Medical Director Clinical Development at SpringWorks Therapeutics
Join to View Full Profile
Springworks Therapeutics100 Washington BlvdStamford, CT 06902
Dr. Lewis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Board certified pediatric hematologist/oncologist working in biotech to advance the science of curing cancer.
Education & Training
Medical University of South CarolinaFellowship, Pediatric Hematology/Oncology, 2007 - 2010
University of MarylandResidency, Pediatrics, 2004 - 2007
Kansas City University of Medicine and Biosciences College of Osteopathic MedicineClass of 2003
Goucher CollegeBA, Biological Sciences, 1994 - 1998
Certifications & Licensure
NJ State License 2013 - 2025
PA State License 2020 - 2022
TN State License 2010 - 2014
SC State License 2007 - 2011
Awards, Honors, & Recognition
- Go Getter Award SpringWorks Therapeutics, 2022
Clinical Trials
- Nirogacestat in Ovarian Granulosa Cell Tumors Start of enrollment: 2022 Aug 30
Publications & Presentations
PubMed
- 5 citationsDefinition of cortical bone involvement in the staging of newly diagnosed pediatric Hodgkin lymphoma: A report from the International Working Group on Staging Evaluati...Jocelyn Lewis, Kathleen M. McCarten, Lars Kurch, Jamie E. Flerlage, Sue C. Kaste
Pediatric Blood & Cancer. 2020-04-01 - 34 citationsStaging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement.Jamie E. Flerlage, Kara M. Kelly, Auke Beishuizen, Steve Y. Cho, Pedro A. de Alarcon
Pediatric Blood & Cancer. 2017-07-01 - 33 citationsOff-Target Function of the Sonic-Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide-Dependent Neutral Sphingomyelinase 2/Ceramide InductionMarisa Meyers-Needham, Jocelyn A. Lewis, Salih Gencer, R. David Sentelle, Sahar A. Saddoughi
Molecular Cancer Therapeutics. 2012-05-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
